← Eichor
Study identifier: NCT07047183 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Condition: Myelodysplastic Neoplasms · Transplantation  ·  Sponsor: Yehui Tan

PhasePhase 2
Planned participants46
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)

This description comes directly from the study's public registry record.

Talk to the study team

Yehui Tan  ·  8615948027438  ·  yhtan@jlu.edu.cn

Yuying Li  ·  8613944135650  ·  lyying1001@jlu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The First Hospital of Jilin UniversityChangchun, Jilin, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07047183